Zoster‑Associated Neuralgia (Post‑Herpetic Neuralgia)

What is Zoster‑Associated Neuralgia?

Zoster‑associated neuralgia, more commonly called post‑herpetic neuralgia (PHN), is a persistent nerve‑pain syndrome that follows an outbreak of varicella‑zoster virus (VZV) – the virus that causes chickenpox and shingles. After a person recovers from the shingles rash, the virus remains dormant in the dorsal root ganglia (clusters of sensory nerve cells). In some individuals, especially older adults or those with weakened immune systems, the nerve fibers become damaged, leading to chronic pain that can last weeks, months, or even years.

PHN is the most common complication of shingles, affecting roughly 10‑20 % of adults who develop shingles and up to 50 % of those over age 70 [1][2]. The pain is usually described as burning, throbbing, stabbing, or a sensation of “electric shocks.” Because the pain originates from damaged peripheral nerves, it often does not respond well to typical analgesics, making early recognition and treatment essential.

Common Causes

PHN is not a disease itself but a complication of shingles. The underlying factors that increase the risk of developing PHN include:

• Age ≥ 60 years – immune senescence reduces the body’s ability to control VZV reactivation.
• Severe acute shingles rash (especially when it involves the face or torso).
• Prodromal pain that lasts >72 hours before the rash appears.
• Immunosuppression (e.g., HIV/AIDS, organ transplantation, chemotherapy).
• Chronic diseases such as diabetes mellitus, chronic kidney disease, or rheumatoid arthritis.
• Psychological stress or depression, which can amplify pain perception.
• Smoking and excessive alcohol use—both impair immune function.
• Genetic predisposition influencing nerve‑growth factor levels.
• Previous episodes of shingles (re‑infection can worsen nerve damage).
• Delayed antiviral therapy (treatment started >72 hours after rash onset).

Associated Symptoms

Aside from the hallmark pain, many patients experience other sensory or autonomic changes in the affected dermatome (skin area supplied by a single spinal nerve):

• Allodynia: Pain triggered by light touch, such as clothing or a gentle breeze.
• Hyperesthesia: Heightened sensitivity to temperature or pressure.
• Paresthesias: Tingling, “pins‑and‑needles,” or numbness.
• Itching or burning sensations.
• Muscle weakness in the same region if motor nerves are involved.
• Sleep disturbance: Pain often worsens at night, leading to insomnia.
• Depression or anxiety: Chronic pain can affect mood and quality of life.
• Visual disturbances if shingles affected the ophthalmic branch of the trigeminal nerve (herpes zoster ophthalmicus).

When to See a Doctor

Prompt medical attention can reduce the severity and duration of PHN. Seek care if you notice any of the following:

• Severe, burning or stabbing pain that persists > 30 days after the shingles rash has healed.
• New or worsening pain that interferes with daily activities, sleep, or mood.
• Allodynia—pain from light touch or clothing.
• Signs of infection at the rash site (increasing redness, swelling, pus).
• Vision changes, eye pain, or facial weakness (possible ocular involvement).
• Fever, headache, or confusion—could signal a more serious complication such as VZV encephalitis.

People with weakened immune systems, pregnant women, or those taking immunosuppressive medications should contact their healthcare provider at the first sign of a shingles rash.

Diagnosis

Diagnosing PHN is primarily clinical, based on a history of shingles and persistent neuropathic pain. The evaluation typically includes:

1. Medical History & Physical Exam – The clinician reviews the date of rash onset, location, severity of the acute episode, and current pain characteristics.
2. Dermatomal Mapping – A visual inspection identifies the exact nerve distribution involved.
3. Neurologic Assessment – Checks for sensory loss, allodynia, or motor deficits.
4. Laboratory Tests (if indicated) – In immunocompromised patients, a PCR test of lesion fluid can confirm VZV; blood work may assess immune status.
5. Imaging – Rarely needed, but MRI or CT may be ordered if atypical pain suggests spinal pathology or central nervous system involvement.

There is no single “test” for PHN; the diagnosis hinges on the temporal relationship between shingles and lingering neuropathic pain.

Treatment Options

Effective management combines pharmacologic therapy, interventional procedures, and self‑care strategies. Early treatment (ideally within 72 hours of rash onset) with antivirals can also lower the risk of PHN developing.

1. Antiviral Medications (during acute shingles)

• Aciclovir, valaciclovir, or famciclovir for 7‑10 days.
• Reduces viral replication, shortens rash duration, and may lessen nerve damage.

2. Pain‑Modifying Drugs (for PHN)

• Anticonvulsants: Gabapentin or pregabalin – first‑line for neuropathic pain; start low and titrate.
• Tricyclic antidepressants (TCAs): Amitriptyline, nortriptyline – effective but watch for anticholinergic side effects in older adults.
• Serotonin‑norepinephrine reuptake inhibitors (SNRIs): Duloxetine or venlafaxine – alternative for patients intolerant to TCAs.
• Topical agents: Lidocaine 5 % patches (single‑use) or capsaicin 8 % patch – useful for localized pain with minimal systemic effects.
• Opioids: Low‑dose tramadol or short‑acting opioid may be considered for breakthrough pain, but long‑term use is discouraged.

3. Interventional Procedures

• Epidural steroid injections: May provide temporary relief for thoracic or lumbar PHN.
• Peripheral nerve blocks: Targeted anesthetic + steroid injection at the affected dermatome.
• Spinal cord stimulation (SCS): Considered for refractory PHN after exhaustive medical therapy.

4. Adjunctive & Home‑Based Therapies

• Cold or warm compresses: Applied for short periods to ease burning sensations.
• Gentle skin care: Use fragrance‑free moisturizers to prevent dryness that can aggravate allodynia.
• Stress‑reduction techniques: Mindfulness, guided imagery, or yoga can lower pain perception.
• Sleep hygiene: Dark, cool bedroom; consider a low‑dose sleep aid if pain interferes with rest.
• Physical activity: Light walking or stretching maintains circulation and can reduce pain chronically.

5. Follow‑Up and Monitoring

Patients should be reassessed every 4–6 weeks after initiating therapy. Dose adjustments, side‑effect monitoring, and escalation to interventional options are guided by pain scores and functional impact.

Prevention Tips

Since PHN is a sequela of shingles, preventing the initial VZV reactivation is the most effective strategy.

• Vaccination:
  • Shingrix (recombinant zoster vaccine) – two doses, 2–6 months apart, approved for adults ≥50 years; >90 % efficacy in preventing shingles and PHN [3].
  • Zostavix (live attenuated) – less effective than Shingrix and not recommended for immunocompromised patients.
• Maintain a healthy immune system: Balanced diet, regular exercise, adequate sleep, and smoking cessation.
• Manage chronic illnesses: Tight glycemic control in diabetes, blood pressure control, and regular follow‑up for autoimmune conditions.
• Prompt antiviral therapy: If a shingles rash appears, seek medical care within 72 hours for antiviral prescription.
• Stress management: Chronic stress can weaken immunity; consider counseling, meditation, or support groups.

Emergency Warning Signs

Key Take‑aways

Zoster‑associated neuralgia is a painful, chronic condition that follows shingles, most often affecting older adults. Early antiviral treatment, adequate pain control, and the use of the recombinant zoster vaccine are the cornerstones of prevention and management. Because the pain can be debilitating and may coexist with mood disorders, a multidisciplinary approach—including medication, interventional therapies, and lifestyle modifications—offers the best chance for relief and improved quality of life.

---

References:

1. Mayo Clinic. Postherpetic Neuralgia. https://www.mayoclinic.org. Accessed April 2026.
2. Centers for Disease Control and Prevention. Shingles (Herpes Zoster). https://www.cdc.gov. Accessed April 2026.
3. Cleveland Clinic. Shingles Vaccine (Shingrix). https://my.clevelandclinic.org. Accessed April 2026.
4. National Institute of Neurological Disorders and Stroke. Postherpetic Neuralgia Information Page. https://www.ninds.nih.gov. Accessed April 2026.
5. World Health Organization. Global Burden of Herpes Zoster. https://www.who.int. 2023.